title: A PET study with [11-C]raclopride in Parkinson's disease: preliminary results on the effect of amantadine on the dopaminergic system.
abstract: Amantadine has been proved to be beneficial in Parkinson's disease. Although it is still uncertain which neurochemical events are modified at therapeutic doses, an increase in dopaminergic tone secondary to NMDA receptor blockade and a direct inhibition of the glutamatergic overactivity have been suggested to be involved in its clinical effects. The aim of this study was to evaluate the effects of amantadine on the dopaminergic system by measuring the in vivo binding of [11-C]raclopride to D2 dopamine receptors in the basal ganglia of 6 patients with idiopathic Parkinson's disease. Each patient underwent a PET study, before and after 14 days of treatment with amantadine (200 mg/day). Repeated treatment with therapeutic doses of amantadine induced a moderate increase in the in vivo binding of [11C]raclopride in the putamen of PD patients. This observation indicates that in PD patients, 200 mg/day amantadine does not produce an increase in extracellular levels of dopamine sufficiently to inhibit raclopride binding or that, if present, is it masked by a concurrent increase in receptor availability, as recently reported in rat striatum.
authors.affiliation: Department of Neurology, IRCCS San Raffaele, Milan, Italy.
authors.forename: M A
authors.initials: MA
authors.lastname: Volonté
authors.forename: R M
authors.initials: RM
authors.lastname: Moresco
authors.forename: C
authors.initials: C
authors.lastname: Gobbo
authors.forename: C
authors.initials: C
authors.lastname: Messa
authors.forename: A
authors.initials: A
authors.lastname: Carpinelli
authors.forename: G
authors.initials: G
authors.lastname: Rizzo
authors.forename: G
authors.initials: G
authors.lastname: Comi
authors.forename: F
authors.initials: F
authors.lastname: Fazio
mesh_terms: D000368:Aged; D000547:Amantadine / Q000378:metabolism* / Q000627:therapeutic use; D001667:Binding, Competitive / Q000187:drug effects / Q000502:physiology; D002250:Carbon Radioisotopes / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents / Q000378:metabolism* / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000378:metabolism; D004347:Drug Interactions / Q000502:physiology; D005260:Female; D006801:Humans; D007980:Levodopa / Q000378:metabolism / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D017729:Presynaptic Terminals / Q000187:drug effects / Q000378:metabolism; D011699:Putamen / Q000000981:diagnostic imaging* / Q000187:drug effects*; D020891:Raclopride / Q000378:metabolism; D011869:Radioligand Assay; D017448:Receptors, Dopamine D2 / Q000187:drug effects* / Q000378:metabolism; D014055:Tomography, Emission-Computed
chemical_list: D002250:Carbon Radioisotopes; D015259:Dopamine Agents; D018492:Dopamine Antagonists; D017448:Receptors, Dopamine D2; D020891:Raclopride; D007980:Levodopa; D000547:Amantadine; D004298:Dopamine